Fibrosis-related pathways in sinoatrial node tissue (N/A)

"Fibrosis-related pathways in sinoatrial node tissue" refers to the molecular signaling cascades and cellular processes that drive the development of fibrotic tissue within and around the sinoatrial node, the primary pacemaker of the heart. The principal pathways involve activation of the TGF-β signaling axis, increased production and deposition of extracellular matrix proteins (such as collagen, periostin, and fibronectin), and secondary inflammatory and remodeling events. These processes lead to alterations in the structure and electrical properties of the SAN and adjacent atrial myocardium, which can precipitate sinus node dysfunction, arrhythmias, and contribute to broader cardiovascular diseases. The key effector molecules include TGF-β1, periostin, connective tissue growth factor, and various collagen isoforms. No single "fibrosis pathway" target exists, but the convergent molecular mediators are being explored as biomarkers and candidate therapeutic targets for intervention in cardiac fibrotic diseases and rhythm disturbances[1][3][6].

Other names

Sinoatrial node fibrosis pathwaysSAN fibrotic signalingFibrotic remodeling in SANCardiac fibrosis pathways (when used in the SAN context)

Mechanisms depend on the drug class, typically: Inhibition of profibrotic signaling (e.g., blocking TGF-β or angiotensin II pathways); Reduction of extracellular matrix synthesis; Suppression of inflammation; Modulation of ion channel remodeling.